PMID- 26770062 OWN - NLM STAT- PubMed-not-MEDLINE DCOM- 20160115 LR - 20220408 IS - 1178-6930 (Print) IS - 1178-6930 (Electronic) IS - 1178-6930 (Linking) VI - 9 DP - 2016 TI - Detection of lung adenocarcinoma with ROS1 rearrangement by IHC, FISH, and RT-PCR and analysis of its clinicopathologic features. PG - 131-8 LID - 10.2147/OTT.S94997 [doi] AB - OBJECTIVE: To detect ROS1 rearrangement using three different assays, including immunohistochemistry (IHC), fluorescence in situ hybridization (FISH), and reverse transcription polymerase chain reaction (RT-PCR), and to analyze the clinicopathologic features of ROS1 rearrangement in patients with lung adenocarcinoma. METHODS: One hundred eighty-three consecutive patients with lung adenocarcinoma with operation and follow-up data were analyzed for ROS1 rearrangement by IHC, FISH, and RT-PCR. PCR products of the RT-PCR-positive samples were sequenced for confirmation of the specific fusion partners. RESULTS: Three of the 183 (1.64%) cases were identified to be positive for ROS1 rearrangement through all three methods. The fusion patterns were CD74 e6-ROS1 e32, CD74 e6-ROS1 e34, and TPM3 e8-ROS1 e35, respectively. FISH-positive cases showed two types of signals, single 3' signals (green) and split red and green signals. Using FISH as a standard method, the sensitivity and specificity of ROS1 IHC with 1+ staining or more were 100% and 96.67%, respectively. The sensitivity and specificity of RT-PCR were both 100%. Univariate analysis identified female sex (P=0.044), Stage I disease (P<0.001), and ROS1-negative status (P=0.022) to be significantly associated with longer overall survival. CONCLUSION: IHC, FISH, and RT-PCR are all effective methods for the detection of ROS1 rearrangement. IHC would be a useful screening method in routine pathologic laboratories. RT-PCR can detect exact fusion patterns. ROS1 rearrangement may be a worse prognostic factor. The exact correlation of ROS1 rearrangement with prognosis and whether different fusion types are correlated with different responses to targeted therapy need to be further investigated. FAU - Cao, Bing AU - Cao B AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Wei, Ping AU - Wei P AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Liu, Zebing AU - Liu Z AD - Department of Pathology, Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, People's Republic of China. FAU - Bi, Rui AU - Bi R AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Lu, Yongming AU - Lu Y AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Zhang, Ling AU - Zhang L AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Zhang, Jing AU - Zhang J AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Yang, Yusi AU - Yang Y AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Shen, Chen AU - Shen C AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Du, Xiang AU - Du X AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. FAU - Zhou, Xiaoyan AU - Zhou X AD - Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; Institute of Pathology, Fudan University, Shanghai, People's Republic of China. LA - eng PT - Journal Article DEP - 20151231 PL - New Zealand TA - Onco Targets Ther JT - OncoTargets and therapy JID - 101514322 PMC - PMC4706119 OTO - NOTNLM OT - FISH OT - IHC OT - ROS1 OT - RT-PCR OT - lung adenocarcinoma OT - rearrangement EDAT- 2016/01/16 06:00 MHDA- 2016/01/16 06:01 PMCR- 2015/12/31 CRDT- 2016/01/16 06:00 PHST- 2016/01/16 06:00 [entrez] PHST- 2016/01/16 06:00 [pubmed] PHST- 2016/01/16 06:01 [medline] PHST- 2015/12/31 00:00 [pmc-release] AID - ott-9-131 [pii] AID - 10.2147/OTT.S94997 [doi] PST - epublish SO - Onco Targets Ther. 2015 Dec 31;9:131-8. doi: 10.2147/OTT.S94997. eCollection 2016.